A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
Inclusion Criteria:
Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the following criteria:
Candidate for systemic therapy and/or phototherapy for psoriasis.
Exclusion Criteria:
Nakagami-gun, Okinawa 903-0215, Japan
Nishi-ku Sakai-shi, Osaka 593-8324, Japan
Shinagawa-KU, Tokyo 141-8625, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Shinjuku-ku, Tokyo 161-8521, Japan
Takaoka-shi, Toyama 9330871, Japan
Morella, Michoacán 58249, Mexico
Smolensk, 214000, Russia
Sungnam-si, Gyeonggi-do 13496, South Korea
Taoyuan Hsien, 10508, Taiwan